Wan-Chuan Tsai

Wan-Chuan Tsai

Auto-generated profile, based on publicly available information

Wan-Chuan Tsai

Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
WTWan-Chuan Tsai
Wan-Chuan Tsai
SHShih-Ping Hsu
Shih-Ping Hsu
YCYen-Ling Chiu
Yen-Ling Chiu
JYJu-Yeh Yang
Ju-Yeh Yang
MPMei-Fen Pai
Mei-Fen Pai
HWHon-Yen Wu
Hon-Yen Wu
Objectives: To assess the cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods: We searched PubMed, MEDLINE, Embase and Cochrane Library for publications up to 17 August 2022. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. Random-effects meta-analyses were performed to pool effect measures across studies. Risk ratios (RRs) with 95% CIs are expressed for composite cardiovascular outcome of cardiovascular death or hospitalisation for heart failure, cardiovascular death, hospitalisation for heart failure, all-cause mortality and composite renal outcome of ≥50% reduction in estimated glomerular filtration rate (eGFR), end-stage kidney disease or renal death. Annual rate of change in eGFR is expressed as the mean difference with 95% CI. Results: We identified four trials with 8927 patients with heart failure or chronic kidney disease (CKD). Compared with placebo, SGLT2 inhibitors showed favourable effects on the composite cardiovascular outcome (RR: 0.79, 95% CI: 0.71 to 0.87; moderate certainty), cardiovascular death (0.85, 0.74 to 0.99; moderate certainty), hospitalisation for heart failure (0.72, 0.62 to 0.82; moderate certainty), the composite renal outcome (0.64, 0.48 to 0.85; low certainty) and the annual rate of change in eGFR (mean difference: 0.99, 0.59 to 1.39 mL/min/1.73 m 2 /year; moderate certainty), while there was no significant difference in all-cause mortality (0.88, 0.77 to 1.01; very low certainty). Moderate certainty evidence indicated that SGLT2 inhibitors reduced the risk of serious adverse events and acute renal failure. Low certainty evidence suggested that SGLT2 inhibitors increased the risk of urinary tract infection and genital infection, while there were no differences in discontinuation due to adverse events, amputation, fracture, hypoglycaemia, ketoacidosis or volume depletion. Conclusions: Evidence of low to moderate certainty suggests that SGLT2 inhibitors provide cardiorenal benefits but have increased risk for urinary tract infection and genital infection in patients without diabetes and with heart failure or CKD. PROSPERO registration number: CRD42021239807.

27 April 2023 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
WTWan-Chuan Tsai
Wan-Chuan Tsai
SHShih-Ping Hsu
Shih-Ping Hsu
YCYen-Ling Chiu
Yen-Ling Chiu
HWHon-Yen Wu
Hon-Yen Wu
CLChia-Chin Luan
Chia-Chin Luan
YPYu-Sen Peng
Yu-Sen Peng

16 June 2021 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
WTWan‐Chuan Tsai
Wan‐Chuan Tsai
YCYen-Ling Chiu
Yen-Ling Chiu
HWHon-Yen Wu
Hon-Yen Wu
WSWen‐Huei Sun
Wen‐Huei Sun
STShan‐Ju Tai
Shan‐Ju Tai
SHShih‐Ping Hsu
Shih‐Ping Hsu

3 May 2023 in JMIR Formative Research
Verified
Journal Article
Open access
JYJu-Yeh Yang
Ju-Yeh Yang
KSKai-Hsiang Shu
Kai-Hsiang Shu
YPYu-Sen Peng
Yu-Sen Peng
SHShih-Ping Hsu
Shih-Ping Hsu
YCYen-Ling Chiu
Yen-Ling Chiu
RKRaymond N Kuo
Raymond N Kuo
Background: Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. Objective: We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. Methods: We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. Results: We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). Conclusions: Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.

17 October 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MAMin-De Ang
Min-De Ang
CCChia-Yun Cheng
Chia-Yun Cheng
WTWan-Chuan Tsai
Wan-Chuan Tsai
PTPing-Hsiu Tsai
Ping-Hsiu Tsai
LHLe-Yin Hsu
Le-Yin Hsu
HWHon-Yen Wu
Hon-Yen Wu
Taiwan has exhibited one of the highest incidence and prevalence rates of dialysis globally, yet updated national data on CKD has been lacking for nearly two decades. We estimated the national CKD prevalence, identified associated risk factors, and evaluated CKD of undetermined etiology (CKDu) in Taiwan. In this cross-sectional study, we analyzed data from 4298 adults age 20 years or older who participated in the 2017–2020 Nutrition and Health Survey in Taiwan, a nationally representative survey employing stratified, three-stage, clustered sampling across 20 administrative divisions. CKD was defined as an eGFR <60 ml/min per 1.73 m 2 or an urine albumin-to-creatinine ratio ≥30 mg/g. Data on demographics, comorbidities, lifestyle factors, and socioeconomic status were collected to identify risk factors associated with CKD. The primary outcome was the national prevalence of CKD. Secondary outcomes included regional CKD prevalence, major risk factors associated with CKD, and characteristics of CKDu. The national CKD prevalence was 10.0%, affecting 1.91 million adults. Prevalence rates for CKD stages 1, 2, 3a, 3b, 4, and 5 were 0.7%, 2.1%, 4.6%, 1.9%, 0.6%, and 0.05%, respectively. CKD prevalence was higher in men (11.9%) than in women (8.1%) and varied regionally, with the highest rate in eastern Taiwan (13.9%), followed by the central (11.5%), southern (11.1%), and northern (8.0%) regions. CKD was independently associated with male sex, older age, diabetes, hypertension, hypertriglyceridemia, gout/hyperuricemia, lower socioeconomic status, and physical inactivity. Only 8% of the patients with CKD were aware of their kidney condition, and CKDu accounted for approximately one-eighth of the CKD population. In conclusion, CKD affects approximately 10% of Taiwanese adults, with marked geographic disparities and low awareness. These findings underscore the need for targeted interventions addressing modifiable risk factors and enhanced screening to improve CKD detection and prevention.

17 June 2025 in International Journal of Dermatology
Verified
Journal Article
Open access
MKMei‐Ju Ko
Mei‐Ju Ko
JCJenny Chiang
Jenny Chiang
CLChun-Hsing Liao
Chun-Hsing Liao
WTWan‐Chuan Tsai
Wan‐Chuan Tsai
PTPing‐Hsiu Tsai
Ping‐Hsiu Tsai
HWHon-Yen Wu
Hon-Yen Wu
Background: While Staphylococcus aureus ( S. aureus ) is a well‐recognized concern in hemodialysis (HD) patients, its role in uremic pruritus remains unknown. This study investigated the impact of S. aureus nasal carriage on the prevalence and severity of uremic pruritus and its association with subsequent infection in HD patients. Methods: We conducted a prospective cohort study from April 2019 to January 2020, enrolling 100 HD patients in Taiwan. Nasal swab cultures determined S. aureus colonization status. Odds ratios (ORs) for uremic pruritus, effect estimates for pruritus intensity, and hazard ratios (HRs) for subsequent S. aureus infections were assessed. Results: S. aureus nasal carriage was detected in 24% of HD patients and was more prevalent among those with uremic pruritus (32.7% vs. 13.3%, p = 0.02). S. aureus nasal carriage was associated with a significantly increased risk of uremic pruritus (OR: 4.21; 95% confidence interval [CI], 1.34–13.24, p < 0.01) and correlated with higher pruritus intensity (effect estimate: 1.18; 95% CI, 0.05–2.30; p = 0.04). During a median follow‐up of 8.97 months, five patients developed S. aureus infections. While S. aureus nasal carriage showed a trend toward an increased risk of subsequent infection, the finding did not reach statistical significance (HR: 50.93; 95% CI, 0.62–4181.02; p = 0.08). Conclusions: S. aureus nasal carriage is significantly associated with the prevalence and severity of uremic pruritus in HD patients. Larger studies are needed to confirm its role in infection risk and to explore decolonization as a potential therapeutic strategy.